Tokyo, Oct. 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059294) titled 'A biomarker study associated with a randomized, prospective phase II trial comparing the efficacy and safety of mFOLFOX6 plus cetuximab (q2w) versus mFOLFOX6 plus bevacizumab as first-line treatment for unresectable right-sided colon cancer with RAS/BRAF wild-type' on Oct. 6.
Study Type:
Observational
Primary Sponsor:
Institute - JR Sendai Hospital
Condition:
Condition - unresectable colon cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - As a specified clinical research study, this project aims to investigate the relationship between treatment efficacy o...